Preclinical studies of [68]Ga-DOTATOC: biodistribution assessment in Syrian rats and evaluation of absorbed dose in human organs
Asia Oceania Journal of Nuclear Medicine and Biology. 2016; 4 (1): 19-29
em Inglês
| IMEMR
| ID: emr-176188
ABSTRACT
Objective[s] Gallium-68 DOTA-DPhe[1]-Tyr[3]-Octreotide [[68]Ga-DOTATOC] has been applied by several European centers for the treatment of a variety of human malignancies. Nevertheless, definitive dosimetric data are yet unavailable. According to the Society of Nuclear Medicine and Molecular Imaging, researchers are investigating the safety and efficacy of this radiotracer to meet Food and Drug Administration requirements. The aim of this study was to introduce the optimized procedure for [68]Ga-DOTATOC preparation, using a novel germanium-68 [[68]Ge]/[68]Ga generator in Iran and evaluate the absorbed doses in numerous organs with high accuracy
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Compostos Organometálicos
/
Ratos
/
Octreotida
/
Receptores de Somatostatina
Limite:
Animais
Idioma:
Inglês
Revista:
Asia Oceania J. Nucl. Med. Biol.
Ano de publicação:
2016
Similares
MEDLINE
...
LILACS
LIS